Area of research
Immunology · Oncology
Research interest
Research interests include Immune cells in cancer, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, and CAR-T cell therapy research.
Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood
Counteracting CAR T cell dysfunction
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
Interactions among myeloid regulatory cells in cancer
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
Melanoma and immunotherapy bridge 2015
Abstract A071: Immune monitoring of ipilimumab treated patients reveals enhanced CD4+ T cell activation correlated with diminished MDSCs
Abstract B026: MDSCs and CD8 effector memory T cells correlate with survival in melanoma patients treated with ipilimumab
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system
Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients
Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2–Dependent Mechanisms
Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production
Abstract A63: Melanoma-educated CD14+ monocytes become myeloid-derived suppressor cell-like and are potent inhibitors of autologous T cells through Cox-2 production and STAT-3 signaling.